Pharma-Biotech Allies Driving the Global Biosimilars Industry
Many large pharma and biotech companies have joined hands and are looking forward to launch biosimilars program, says RNCOS in its latest research study.
- (1888PressRelease) July 08, 2011 - As per our new research report "Global Biosimilars Market Analysis", biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech's rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon's biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Further, more and more drugmakers are realizing the potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. For instance, Watson Pharmaceuticals entered an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals to develop and commercialize Itero's biosimilar for the treatment of female infertility. Besides, Amgen has considered entering the "biosimilars" space, particularly in emerging markets like Asia and South America.
Further, we have done thorough research and prudent analysis of the global biosimilars market and identified some critical factors acting as a catalyst for the industry's current and future growth outlook. The report reveals that, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars access to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
The report reveals that, as many biologic patents are in the way to face expirations in the coming years, it is expected that many private players will pour in their investments as well as their interests in developing biosimilars versions. Besides, considerable positive regulatory developments will be observed in the sector that will be a result of the mounting pressure from governments, insurers and patients groups to reduce costs.
"Global Biosimilars Market Analysis" provides extensive information and rational analysis of the global biosimilars market. It has thoroughly examined current market drivers & restraints, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in coming years. The report also provides an insight into different biosimilars marketed products along with country-wise analysis to present an overview of the developments taking place in the global biosimilars industry. Further, a review of product introductions/innovations and recent industry activity has been covered in the report.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM345.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com/promotion.htm
About RNCOS:
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals study and analyze the industry and its various components, with comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the consultants in meeting their objectives in a cost-effective and timely manner.
###
space
space
Contact Information
- Shushmul Maheshwari
- Rncos
- B 129 Sector 6
- Noida 201301
- 201301
- Voice: 91-120-4224-700
- Visit our Site
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam